Cargando…

Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial

INTRODUCTION: Itraconazole follows non-linear pharmacokinetics and hence is recommended once daily, but in real-world practice, is commonly prescribed as twice daily. Hence, this study aimed to evaluate the efficacy and safety of super-bioavailable-itraconazole-130 mg (SB-130) and conventional-itrac...

Descripción completa

Detalles Bibliográficos
Autores principales: Shenoy, Manjunath M, De, Abhishek, Shah, Bela, Das, Anupam, Saraswat, Abir, Lahiri, Koushik, Yadav, Sheetal, Sarda, Aarti, Chakraborty, Disha, J, Dharmender, Kamat, Shruti, Doshi, Yashika, Gonsalves, Nelry, Choudhary, Ankita, Dhoot, Dhiraj, Mahadkar, Namrata, Bhushan, Sumit, Gadkari, Rujuta, Barkate, Hanmant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520254/
https://www.ncbi.nlm.nih.gov/pubmed/37766823
http://dx.doi.org/10.2147/DDDT.S421583
_version_ 1785109877344960512
author Shenoy, Manjunath M
De, Abhishek
Shah, Bela
Das, Anupam
Saraswat, Abir
Lahiri, Koushik
Yadav, Sheetal
Sarda, Aarti
Chakraborty, Disha
J, Dharmender
Kamat, Shruti
Doshi, Yashika
Gonsalves, Nelry
Choudhary, Ankita
Dhoot, Dhiraj
Mahadkar, Namrata
Bhushan, Sumit
Gadkari, Rujuta
Barkate, Hanmant
author_facet Shenoy, Manjunath M
De, Abhishek
Shah, Bela
Das, Anupam
Saraswat, Abir
Lahiri, Koushik
Yadav, Sheetal
Sarda, Aarti
Chakraborty, Disha
J, Dharmender
Kamat, Shruti
Doshi, Yashika
Gonsalves, Nelry
Choudhary, Ankita
Dhoot, Dhiraj
Mahadkar, Namrata
Bhushan, Sumit
Gadkari, Rujuta
Barkate, Hanmant
author_sort Shenoy, Manjunath M
collection PubMed
description INTRODUCTION: Itraconazole follows non-linear pharmacokinetics and hence is recommended once daily, but in real-world practice, is commonly prescribed as twice daily. Hence, this study aimed to evaluate the efficacy and safety of super-bioavailable-itraconazole-130 mg (SB-130) and conventional-itraconazole-200 mg (CITZ-200) once daily compared with conventional-itraconazole-100 mg (CITZ-100) twice daily in glabrous tinea. METHODS: A total of 261 eligible patients were enrolled in this prospective, randomized, clinical study from December-2021 to August-2022 at seven centers in India. Efficacy and safety assessments were done at week-3 and 6, with follow-up at week-10 for relapse. The primary objective was to assess the proportion of patients who achieved complete cure at week-6 following treatment in all itraconazole groups. The secondary outcomes were safety and clinical and mycological cure rates. RESULTS: Of 261 patients, 240 were included in the analysis. At week-6, 140 patients were completely cured; thus, overall cure rate was 58.33%. Fifty-five patients (69%) in SB-130 while 47/77 (61%) and 38/83 (46%) patients were completely cured in CITZ-200 and CITZ-100 groups respectively (p<0.05; SB-130: CITZ-100, p=0.32; SB-130: CITZ-200, p=0.058; CITZ-200: CITZ-100). There was no statistical difference in the mycological cure rate and area clearance rate between any of the groups (p=0.14); however, a statistically significant difference was noted for OD dosing over BD dosing in achieving clinical cure rates (p<0.05). A total of 13/140 patients (9%) relapsed following complete cure, with no statistically significant difference between any of the groups (p=0.50). All treatments were safe and well-tolerated, with no discontinuation. CONCLUSION: In this clinical study, moderate efficacy with all doses of ITZ was reported but was better with OD dosing. Although there was no statistical difference between SB-130 and CITZ-200, SB-130 may be preferred over CITZ-200 owing to the advantage of SB over the conventional ITZ.
format Online
Article
Text
id pubmed-10520254
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105202542023-09-27 Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial Shenoy, Manjunath M De, Abhishek Shah, Bela Das, Anupam Saraswat, Abir Lahiri, Koushik Yadav, Sheetal Sarda, Aarti Chakraborty, Disha J, Dharmender Kamat, Shruti Doshi, Yashika Gonsalves, Nelry Choudhary, Ankita Dhoot, Dhiraj Mahadkar, Namrata Bhushan, Sumit Gadkari, Rujuta Barkate, Hanmant Drug Des Devel Ther Original Research INTRODUCTION: Itraconazole follows non-linear pharmacokinetics and hence is recommended once daily, but in real-world practice, is commonly prescribed as twice daily. Hence, this study aimed to evaluate the efficacy and safety of super-bioavailable-itraconazole-130 mg (SB-130) and conventional-itraconazole-200 mg (CITZ-200) once daily compared with conventional-itraconazole-100 mg (CITZ-100) twice daily in glabrous tinea. METHODS: A total of 261 eligible patients were enrolled in this prospective, randomized, clinical study from December-2021 to August-2022 at seven centers in India. Efficacy and safety assessments were done at week-3 and 6, with follow-up at week-10 for relapse. The primary objective was to assess the proportion of patients who achieved complete cure at week-6 following treatment in all itraconazole groups. The secondary outcomes were safety and clinical and mycological cure rates. RESULTS: Of 261 patients, 240 were included in the analysis. At week-6, 140 patients were completely cured; thus, overall cure rate was 58.33%. Fifty-five patients (69%) in SB-130 while 47/77 (61%) and 38/83 (46%) patients were completely cured in CITZ-200 and CITZ-100 groups respectively (p<0.05; SB-130: CITZ-100, p=0.32; SB-130: CITZ-200, p=0.058; CITZ-200: CITZ-100). There was no statistical difference in the mycological cure rate and area clearance rate between any of the groups (p=0.14); however, a statistically significant difference was noted for OD dosing over BD dosing in achieving clinical cure rates (p<0.05). A total of 13/140 patients (9%) relapsed following complete cure, with no statistically significant difference between any of the groups (p=0.50). All treatments were safe and well-tolerated, with no discontinuation. CONCLUSION: In this clinical study, moderate efficacy with all doses of ITZ was reported but was better with OD dosing. Although there was no statistical difference between SB-130 and CITZ-200, SB-130 may be preferred over CITZ-200 owing to the advantage of SB over the conventional ITZ. Dove 2023-09-21 /pmc/articles/PMC10520254/ /pubmed/37766823 http://dx.doi.org/10.2147/DDDT.S421583 Text en © 2023 Shenoy et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Shenoy, Manjunath M
De, Abhishek
Shah, Bela
Das, Anupam
Saraswat, Abir
Lahiri, Koushik
Yadav, Sheetal
Sarda, Aarti
Chakraborty, Disha
J, Dharmender
Kamat, Shruti
Doshi, Yashika
Gonsalves, Nelry
Choudhary, Ankita
Dhoot, Dhiraj
Mahadkar, Namrata
Bhushan, Sumit
Gadkari, Rujuta
Barkate, Hanmant
Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial
title Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial
title_full Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial
title_fullStr Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial
title_full_unstemmed Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial
title_short Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial
title_sort efficacy of super-bioavailable itraconazole and conventional itraconazole at different dosing regimens in glabrous tinea infection - a randomized clinical trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520254/
https://www.ncbi.nlm.nih.gov/pubmed/37766823
http://dx.doi.org/10.2147/DDDT.S421583
work_keys_str_mv AT shenoymanjunathm efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT deabhishek efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT shahbela efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT dasanupam efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT saraswatabir efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT lahirikoushik efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT yadavsheetal efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT sardaaarti efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT chakrabortydisha efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT jdharmender efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT kamatshruti efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT doshiyashika efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT gonsalvesnelry efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT choudharyankita efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT dhootdhiraj efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT mahadkarnamrata efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT bhushansumit efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT gadkarirujuta efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial
AT barkatehanmant efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial